Clinical Trial Update: Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START [Phase 4]

View source ↗

Summary

This clinical trial update reports completion of a Phase 4 study evaluating early SD-OCT changes after starting intravitreal aflibercept (EYLEA) in neovascular …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Neovascular Age-related Macular Degeneration of All Subtypes | Phase 4 | Status: COMPLETED